



MOA

Step-wise approach to asthma therapy

- * Inhaled Long-acting Beta-2 Agonists/ LABA
- * Inhaled Corticosteroids/ ICS
- * oral Corticosteroids/ OCS

			LABA	LABA
		LABA	ICS High dose	ICS High dose
	ICS Low dose	ICS Low dose		
	Short-acting β ₂ -agonist as required for symptom relief			
Mild intermittent	Mild persistent	Moderate persistent	Severe persistent	Very severe persistent

Step-wise Approach to Asthma Therapy

- Quick relief medications**
 - 1) inhaled SHORT acting Beta-2 AGONISTS
 - 2) inhaled anti-cholinergics
 - 3) SYSTEMIC Corticosteroids
- Long-term control medications**
 - 1) TOPICAL/ INHALED Corticosteroids
 - 2) INHALED Cromolyn Na & Nedocromil
 - 3) ORAL Methyl-xanthines= Theo-phyllines
 - 4) INHALED long acting Beta-2 AGONISTS/ LABAs
 - 5) ORAL leukotriene modifiers/ LTRAs

Relievers / Controllers

Treatment of Bronchial Asthma

Intro

- Definition of Asthma**
 - = CHRONIC [inflammatory] disorder with [intermittent] narrowing of the airways
 - characterized by [resistance to flow] over short periods of time, in the intrapulmonary airways
- Factors in the treatment strategy**
 - 1/ asthma is a CHRONIC condition>> needs CHRONIC therapy
 - 2/ goal of therapy>> NORMAL function
 - 1- MINIMAL [symptoms] even during sleep
 - 2- NO or INFREQUENT [ACUTE episodes]
 - 3- rare need for [beta AGONIST] inhaler therapy
 - 4- NO limitation of activities... even sports
 - 5- [peak flow rate] variability less than 20%
 - 6- NO or MINIMAL adverse effects from drugs
 - 3/ the condition is heterogeneous in terms of:
 - cause or trigger mechanism
 - 1/ exercise
 - 2/ cold air
 - 3/ cigarette smoking
 - 4/ stress/ anxiety situations
 - 5/ animal dander's... cats, dogs
 - 6/ allergens... grass, trees, molds, cockroach
 - 7/ pollutants... sulfur dioxide, ozone
 - 8/ fumes/ toxic substances
 - 9/ medications... ASA, NSAID's
 - extent of [broncho-constriction]
 - degree of [inflammation]
 - 4/ the course is UNPREDICTABLE
 - 5/ therapy must be INDIVIDUALISED

- Risk of NOT treating Asthma**
 - 1) poor or no control of the patient's asthma
 - 2) accelerated decline in the function of the patient's lungs
 - 3) increased number of attacks of asthma
 - 4) poorer response to therapy if started late
 - 5) increased mortality from asthma
- Pathogenesis of RE-exposure**
 - Early response>> prevented by [broncho-dilators]
 - Late response>> prevented by [corticosteroids]

- Diagnosis of Asthma**
 - 1) Subjective
 - Cough>> usually in [spasms]>> to the point of vomiting>> night-time worse than day-time>> may follow exposure to [cold air] [exercise] [URI/ infection] [allergen]
 - Dyspnea>> wheezing>> sputum
 - Past history of [bronchiolitis] as a child
 - Family history
 - 2) Objective
 - diminished [peak expiratory flow rate/ PEFr]
 - reduced [mean] & [forced expiratory flow rate/ FEFR]
 - reversibility with [broncho-dilators]
 - heightened response to [Methacholine Test]
 - increase in [expire nitric oxide/ NO]
 - increase in [inflammatory mediators] & [their metabolic products] in body fluids

- Myths & Misconceptions**
 - patient & physician [steroido-phobia]
 - asthma is an emotional illness
 - asthma is an ACUTE disease
 - asthma medications are addictive
 - asthma medications become IN-effective if they are used regularly
 - asthma is NOT a fatal illness

- Survey of the changing therapy of asthma by decade**
 - 1960's
 - Amino-phylline
 - Epinephrine
 - Ephedrine
 - 1970's
 - Beta AGONISTS
 - Theo-phyllines
 - Beclo-methasone
 - 1980's
 - Cromolyn
 - Ipra-tropium
 - Beta AGONISTS
 - 1990's
 - Inhaled Corticosteroids
 - Cromolyn
 - Ipra-tropium
 - Inhaled Corticosteroids
 - Beta AGONISTS
 - Theo-phylline
 - Leukotriene inhibitors
 - 2000's
 - Corticosteroids + LABA/ long acting beta agonist
 - LTRAs/ leukotriene receptor ANTAGONISTS
 - Theo-phylline
 - Cromolyn
 - Ipra-tropium
 - Tio-tropium
 - 2010's
 - PREVENTION including [gene therapy]